#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chordoma Cutaneous lupus erythematosus MELAS syndrome Fibrous dysplasia of bone Angiosarcoma Chronic myelomonocytic leukaemia Pancreatic carcinoma metastatic Inclusion body myositis Heavy menstrual bleeding Renal cancer metastatic Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Retinitis pigmentosa Indolent systemic mastocytosis Philadelphia chromosome positive Homocystinuria More trials…

    Learn about Rare Diseases

    Optic glioma – Treatment Angelman’s syndrome – Trials in Disease KBG syndrome – Treatment Thrombotic thrombocytopenic purpura – Treatment Tuberous sclerosis complex Ehlers-Danlos syndrome – Life with Disease Hereditary neuropathic amyloidosis Krabbe’s disease Hereditary motor and sensory neuropathy – Diagnostics Factor IX deficiency More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Zidesamtinib Fluciclovine (18F) Aspartic Acid Nirogacestat Hydrobromide Ly3819469 Sodium Mirikizumab Patritumab Deruxtecan Teriflunomide Diazepam Sodium Iodide (131I) Rtp-026 Sodium Amantadine Hydrochloride Bhv-7000 Exagamglogene Autotemcel Navtemadlin Bleomycin 18F-Psma-1007 Romidepsin Ozanimod Hydrochloride RO7284755 More therapies…

    Learn about Your Condition

    Stress cardiomyopathy Colonoscopy Critical illness Brain injury Infertility male Liver disorder Complicated appendicitis Rhabdoid tumour Pleomorphic leiomyosarcoma Tissue anoxia Herpes virus infection Diabetic foot Osteosarcoma recurrent Juvenile absence epilepsy Constipation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut De Cancerologie De Lorraine

Institut De Cancerologie De Lorraine

6 Avenue De Bourgogne, Cs 30519, Vandoeuvre Les Nancy, 54519, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Hyperthermic Intraperitoneal Chemotherapy with Cisplatin for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Cisplatin
    France

  • Study of Carboplatin, Paclitaxel, and Cetuximab for Patients with Recurrent or Metastatic Head and Neck Cancer After Pembrolizumab Treatment Failure

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Carboplatin
    • Cetuximab
    • Paclitaxel
    France

  • Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    France

  • Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Avelumab
    • Carboplatin
    • Cetuximab
    France

  • Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capecitabine
    • Pembrolizumab
    France

  • Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Dactinomycin
    • Regorafenib
    • Vinorelbine Tartrate
    Austria Belgium Czechia Denmark Finland France +10

  • Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cemiplimab
    • Ipilimumab
    • Atezolizumab
    France

  • Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Vinorelbine
    • Zanidatamab
    Austria Belgium France Germany Greece Italy +2

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroblastoma
    Investigated Drugs:
    • Dinutuximab Beta
    • Melphalan
    • Thiotepa
    Austria Belgium Czechia Denmark Finland France +11

  • Study on EXL01 with Nivolumab and FOLFOX for First-Line Treatment in Patients with PD-L1 CPS ≥5 Metastatic Gastric Cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • ANHYDROUS CALCIUM FOLINATE
    • Exl01
    • Fluorouracil Sodium
    France
Previous Page
1 … 3 4 5 6 7 … 18
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!